BioSpace News Archive

Eargo, Inc. announced the Company received a letter from The Nasdaq Stock Market LLC indicating that, since the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended September 30, 2021, the Company no longer complies with Nasdaq Listing Rule 5250 for continued listing.

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that members of the Company’s management team will be presenting virtually at the following conferences.

DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced that data from the Phase 1 study of DNX-2401 in diffuse intrinsic pontine glioma (DIPG) was presented in an oral presentation at the 26th Annual Meeting and Education Day of the Society for Neuro-oncology (SNO).

Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the appointment of Linda Szyper to the Company’s Board of Directors.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the company will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it entered into an exclusive license agreement with GlaxoSmithKline (LSE/NYSE: GSK) under which GSK will develop and commercialize ARO-HSD, Arrowhead’s investigational RNA interference (RNAi) therapeutic in a Phase 1/2 trial that is currently being developed as a treatment for patients with nonalcoholic steatohepatitis (NASH).

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that management will participate in a fireside chat at the upcoming Evercore ISI HealthCONx 2021 Conference.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal fourth quarter and year ended September 30, 2021.

GlycoMimetics, Inc. announced that Lisa DeLuca, Ph.D., has joined its executive leadership team as Vice President, Regulatory Affairs.

Neuronetics, Inc. (NASDAQ: STIM), today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference.